Kancera: Positive pre-IND feedback from the FDA - Redeye
Redeye comments on this morning’s news that Kancera has received positive feedback on the planned clinical program for KAND567 in ST-elevation myocardial infarction.
ANNONS
Redeye comments on this morning’s news that Kancera has received positive feedback on the planned clinical program for KAND567 in ST-elevation myocardial infarction.